Cargando…
Therapeutic use of specific tumour necrosis factor inhibitors in inflammatory diseases including COVID-19
Coronavirus disease 2019 (COVID-19) has caused significant devastation globally. Despite the development of several vaccines, with uncertainty around global uptake and vaccine efficacy, the need for effective therapeutic agents remains. Increased levels of cytokines including tumour necrosis factor...
Autores principales: | Patel, Serena, Wadhwa, Meenu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Masson SAS.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8162906/ https://www.ncbi.nlm.nih.gov/pubmed/34126316 http://dx.doi.org/10.1016/j.biopha.2021.111785 |
Ejemplares similares
-
Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues
por: Peyrin-Biroulet, Laurent, et al.
Publicado: (2021) -
EP21 Tumour necrosis factor inhibitor for the treatment of refractory extra-pulmonary disease including sarcoid arthritis and myositis
por: Rampes, Sanketh, et al.
Publicado: (2020) -
TAK1: a potent tumour necrosis factor inhibitor for the treatment of inflammatory diseases
por: Totzke, Juliane, et al.
Publicado: (2020) -
Smoking status and cause-specific discontinuation of tumour necrosis factor inhibitors in axial spondyloarthritis
por: Zhao, Sizheng Steven, et al.
Publicado: (2019) -
Tumour necrosis factor-dependent inflammatory cartilage destruction
por: Korb, A, et al.
Publicado: (2007)